<DOC>
	<DOC>NCT00681811</DOC>
	<brief_summary>This is a multi-center, open-label, extension study of patients with late infantile MLD who have previously completed clinical study HGT-MLD-048 (NCT00633139), defined as the completion of all Week 52 procedures. This group of patients will be offered ongoing treatment with HGT-1111 in this protocol. One infusion will be given every other week until the product is commercially available, the patient discontinues, or the study is terminated by the Sponsor, provided no safety issues have emerged.</brief_summary>
	<brief_title>Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD</brief_title>
	<detailed_description>The primary objective of this study is to provide ongoing treatment of HGT-1111 to patients who have completed study HGT-MLD-048 (previously study rhASA-03 - NCT00633139) until HGT-1111 is commercially available or the study is terminated by the Sponsor, provided no safety concerns have emerged. The secondary objective of this study is to monitor disease progression and the safety profile of HGT-1111 administered to patients who have completed study HGT-MLD-048 (NCT00633139).</detailed_description>
	<mesh_term>Leukodystrophy, Metachromatic</mesh_term>
	<criteria>1. Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any studyrelated activities (Trialrelated activities are any procedures that would not have been performed during normal management of the subject) 2. Completion of study HGTMLD048 (NCT00633139) 3. The subject and his/her guardian(s) must have the ability to comply with the protocol 1. Spasticity so severe to inhibit transportation 2. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition that, in the opinion of the Investigator, would preclude participation in the trial 3. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Metazyme</keyword>
	<keyword>Late Infantile Metachromatic Leukodystrophy</keyword>
</DOC>